AN2 Therapeutics (ANTX) Amortizatization of Intangibles (2021 - 2026)
AN2 Therapeutics (ANTX) reported Amortizatization of Intangibles of $81000.0 for Q1 2026, down 81.72% year-over-year from $443000.0 in Q1 2025, and down 30.77% quarter-over-quarter from $117000.0 in Q4 2025.
AN2 Therapeutics (ANTX) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Amortizatization of Intangibles data on file, last reported at $81000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $81000.0, down 81.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $708000.0 (down 73.09% YoY), and the FY2025 annual result was $1.1 million, down 67.37% from the prior year.
- Amortizatization of Intangibles fell to $81000.0 in Q1 2026 per ANTX's latest filing, from $117000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $1.3 million in Q4 2023 and troughed at -$1000.0 in Q1 2022.
- A 5-year average of $469235.3 and a median of $435000.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2026: Amortizatization of Intangibles soared 43600.0% in 2023, then slumped 81.72% in 2026.
- A 5-year view of Amortizatization of Intangibles shows it stood at $375000.0 in 2022, then soared by 248.27% to $1.3 million in 2023, then plunged by 56.58% to $567000.0 in 2024, then slumped by 79.37% to $117000.0 in 2025, then slumped by 30.77% to $81000.0 in 2026.
- Business Quant data shows ANTX's Amortizatization of Intangibles at $81000.0 in Q1 2026, $117000.0 in Q4 2025, and $211000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | 81,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81,000.00 |
| Mar 31, 2026 | 81,000.00 |
| Dec 31, 2025 | 117,000.00 |
| Dec 31, 2025 | 117,000.00 |
| Sep 30, 2025 | 211,000.00 |
| Sep 30, 2025 | 211,000.00 |
| Jun 30, 2025 | 299,000.00 |
| Jun 30, 2025 | 299,000.00 |
| Mar 31, 2025 | 443,000.00 |
| Mar 31, 2025 | 443,000.00 |
| Dec 31, 2024 | 567,000.00 |
| Dec 31, 2024 | 567,000.00 |
| Sep 30, 2024 | 731,000.00 |
| Sep 30, 2024 | 731,000.00 |
| Jun 30, 2024 | 890,000.00 |
| Jun 30, 2024 | 890,000.00 |
| Mar 31, 2024 | 1.09 Mn |
| Mar 31, 2024 | 1.09 Mn |
| Dec 31, 2023 | 1.31 Mn |
| Dec 31, 2023 | 1.31 Mn |